Why is Exubera being withdrawn?

BMJ

Volumn 335, Issue 7630, 2007, Pages 1156-

  Bailey, Clifford J ^a   Barnett, Anthony H ^b  

^a ASTON UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85007764407     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.39409.507662.94     Document Type: Article

References (5)

1. Ceglia L, Lau J, Pittas AG. Meta-analysis: efficacy and safety of inhaled insulin therapy in adults with diabetes mellitus. Ann Intern Med 2006; 145: 665–675.
2. Bellary S, Barnett AH. Inhaled insulin: overcoming barriers to insulin therapy? Br J Diabetes Vasc Dis 2006; 6: 103–108.
3. Skyler JS, Jovanovic L, Klioze S, Reis S, Duggan W, Inhaled Insulin Type 1 Diabetes Study Group. Two-year safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 1 diabetes. Diabetes Care 2007; 30: 579–585.
4. Rosenstock J, Cappelleri JC, Bolinder B, Gerber RA. Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes. Diabetes Care 2004; 27: 1318–1323.
5. National Institute for Health and Clinical Excellence. Inhaled insulin for the treatment of diabetes (types 1 and 2).www.nice.org.uk/TA113quickrefguide